Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.

Pfizer Inc. announced that it has settled its litigation against Teva Pharmaceuticals, USA Inc., relating to Pfizer's patent covering the use of Viagra® to treat erectile dysfunction (sildenafil citrate 25, 50, and 100 mg tablets), which expires in April 2020 (including pediatric exclusivity).

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) have announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate against Alzheimer's disease.

AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy (LD).

UCB has today announced the successful completion of a £3.29 million investment in new, cutting-edge robotic laboratory equipment and purpose-built technology at its UK immunology research centre of excellence. The investment centres on an automated antibody discovery platform, designed and built especially for UCB by Farnborough based robotic laboratory experts company Peak Analysis & Automation Ltd (PAA).

Pfizer Inc. (NYSE: PFE) has announced an update of its clinical trial data access policy that will simplify and broaden access to information gathered in Pfizer-sponsored clinical trials. The updated policy builds upon and expands the company's established methods of clinical trial information sharing, including Pfizer's long track record of submitting for publication results from all interventional clinical trials in patients and its pioneering efforts to provide clinical trial results and data to study participants.

Novartis senior executives have gathered in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company's innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, local talent development and the company's Malaria Initiative.